Veloxis wins $1.3B buyout, and the new owner plans to follow up with new deals
Japan’s Asahi Kasei Pharma has stepped up with a deal to buy out Copenhagen-based Veloxis Pharmaceuticals for $1.3 billion, bagging an organ rejection drug in the process.
The deal comes 17 years after Veloxis was founded, and the two big shareholders — Novo Holdings and Lundbeckfond Invest — have both signed off on the buyout. The biotech makes an immunosuppressive drug called Envarsus XR for kidney transplants.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.